Earnings results for BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc. is expected* to report earnings on 04/29/2021 after market close. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.07. The reported EPS for the same quarter last year was $0.38.
BioMarin Pharmaceutical last announced its earnings data on February 25th, 2021. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.18. The business earned $452.12 million during the quarter, compared to the consensus estimate of $447.17 million. BioMarin Pharmaceutical has generated $0.07 earnings per share over the last year and currently has a price-to-earnings ratio of 18.4. BioMarin Pharmaceutical has confirmed that its next quarterly earnings report will be published on Thursday, April 29th, 2021.
Analyst Opinion on BioMarin Pharmaceutical (NASDAQ:BMRN)
19 Wall Street analysts have issued ratings and price targets for BioMarin Pharmaceutical in the last 12 months. Their average twelve-month price target is $117.36, predicting that the stock has a possible upside of 45.87%. The high price target for BMRN is $218.00 and the low price target for BMRN is $77.00. There are currently 8 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of “Buy.”
BioMarin Pharmaceutical has received a consensus rating of Buy. The company’s average rating score is 2.58, and is based on 11 buy ratings, 8 hold ratings, and no sell ratings. According to analysts’ consensus price target of $117.36, BioMarin Pharmaceutical has a forecasted upside of 45.9% from its current price of $80.46. BioMarin Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Dividend Strength: BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical does not currently pay a dividend. BioMarin Pharmaceutical does not have a long track record of dividend growth.
Insiders buying/selling: BioMarin Pharmaceutical (NASDAQ:BMRN)
In the past three months, BioMarin Pharmaceutical insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,632,046.00 in company stock. Only 2.15% of the stock of BioMarin Pharmaceutical is held by insiders. 97.65% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of BioMarin Pharmaceutical (NASDAQ:BMRN
Earnings for BioMarin Pharmaceutical are expected to decrease by -11.67% in the coming year, from $0.60 to $0.53 per share. The P/E ratio of BioMarin Pharmaceutical is 18.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.88. The P/E ratio of BioMarin Pharmaceutical is 18.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 46.05. BioMarin Pharmaceutical has a PEG Ratio of 3.89. PEG Ratios above 1 indicate that a company could be overvalued. BioMarin Pharmaceutical has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here